azacitidine has been researched along with Bone Loss, Osteoclastic in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fang, Z; Guan, H; Li, F; Li, J; Li, Y; Mi, B; Tan, P; Wu, W; Zhang, Y | 1 |
Kobyliansky, E; Mizrahi, L; Savion, S; Shahar, R; Toder, V; Torchinsky, A | 1 |
2 other study(ies) available for azacitidine and Bone Loss, Osteoclastic
Article | Year |
---|---|
Decitabine represses osteoclastogenesis through inhibition of RANK and NF-κB.
Topics: Animals; Azacitidine; Bone Resorption; Cell Differentiation; Cell Line; Cells, Cultured; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Mice, Inbred C57BL; NF-kappa B; Osteoclasts; RANK Ligand; Signal Transduction; Transcription Factor AP-1 | 2015 |
Bone loss in adult offspring induced by low-dose exposure to teratogens.
Topics: Acid Phosphatase; Aging; Animals; Apoptosis; Azacitidine; Bone Resorption; Embryo, Mammalian; Female; Femur; Gene Expression Profiling; Gene Expression Regulation, Developmental; Hindlimb; Isoenzymes; Limb Buds; Mice; Mice, Inbred ICR; MicroRNAs; Osteoblasts; Osteogenesis; Osteoprotegerin; Pregnancy; Prenatal Exposure Delayed Effects; RANK Ligand; Reproduction; Tartrate-Resistant Acid Phosphatase; Teratogens; X-Ray Microtomography | 2012 |